Back to top
more

Intercept Pharmaceuticals, Inc. (ICPT)

(Delayed Data from NSDQ)

$89.92 USD

89.92
705,568

+1.71 (1.94%)

Updated May 3, 2019 04:00 PM ET

After-Market: $89.98 (%) 5:22 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.03%
2Buy17.70%
3Hold9.37%
4Sell5.03%
5Strong Sell2.48%
S&P50011.19%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

NA Value NA Growth NA Momentum NA VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

NA

Industry: NA

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

Intercept (ICPT) Up 0.4% Since Last Earnings Report: Can It Continue?

by Zacks Equity Research

Intercept (ICPT) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Gilead (GILD) Expands NASH Collaboration With Novo Nordisk

by Zacks Equity Research

Gilead (GILD) expands collaboration with Novo Nordisk for developing NASH treatments.

Intercept's (ICPT) Q4 Loss Wider than Expected, Sales Miss

by Zacks Equity Research

Intercept (ICPT) posts a wider loss and misses on sales in the fourth quarter of 2020.

Intercept Pharmaceuticals (ICPT) Reports Q4 Loss, Misses Revenue Estimates

by Zacks Equity Research

Intercept (ICPT) delivered earnings and revenue surprises of -1.94% and -0.99%, respectively, for the quarter ended December 2020. Do the numbers hold clues to what lies ahead for the stock?

Cronos (CRON) to Report Q4 Earnings: What's in the Offing?

by Zacks Equity Research

Investors will focus on regular top and bottom-line numbers along with its pipeline progress, when Cronos (CRON) reports Q4 results.

Intercept (ICPT) Down 14.4% Since Last Earnings Report: Can It Rebound?

by Zacks Equity Research

Intercept (ICPT) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Gilead (GILD), Novo Nordisk Post Upbeat Data From NASH Study

by Zacks Equity Research

Gilead (GILD) and Novo Nordisk present favorable outcomes from a mid-stage study in NASH patients.

Intercept's (ICPT) Q3 Loss Wider Than Expected, Sales Beat

by Zacks Equity Research

Intercept (ICPT) posts a wider loss but beats on sales in the third quarter of 2020.

Intercept Pharmaceuticals (ICPT) Reports Q3 Loss, Tops Revenue Estimates

by Zacks Equity Research

Intercept (ICPT) delivered earnings and revenue surprises of -2.55% and 2.75%, respectively, for the quarter ended September 2020. Do the numbers hold clues to what lies ahead for the stock?

Intercept (ICPT) Down 16.2% Since Last Earnings Report: Can It Rebound?

by Zacks Equity Research

Intercept (ICPT) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Intercept's (ICPT) Stock Rises After Layoff Announcement

by Zacks Equity Research

Intercept (ICPT) plans to lay off its workforce to save costs and streamline operations.

Intercept (ICPT) Posts New Positive Results on NASH Drug

by Zacks Equity Research

Intercept (ICPT) releases new favorable outcome on OCA from the REGENERATE study, which evaluated patients with liver fibrosis due to NASH.

Intercept (ICPT) Catches Eye: Stock Jumps 8.4%

by Zacks Equity Research

Intercept (ICPT) saw a big move last session, as its shares jumped more than 8% on the day, amid huge volumes.

Intercept's (ICPT) Q2 Earnings and Revenues Beat Estimates

by Zacks Equity Research

Intercept (ICPT) reports better-than-expected results for the second quarter of 2020.

Intercept Pharmaceuticals (ICPT) Reports Q2 Loss, Tops Revenue Estimates

by Zacks Equity Research

Intercept (ICPT) delivered earnings and revenue surprises of 34.69% and 8.59%, respectively, for the quarter ended June 2020. Do the numbers hold clues to what lies ahead for the stock?

Kinjel Shah headshot

Biotech Stock Q2 Earnings on Aug 10: NVAX, ICPT & More

by Kinjel Shah

Let us take a look at five small biotech companies, NVAX, ICPT, FOLD, RETA, HALO, which are gearing up for their earnings release.

Why Earnings Season Could Be Great for Intercept (ICPT)

by Zacks Equity Research

Intercept (ICPT) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.

Tilray (TLRY) to Report Q2 Earnings: What's in the Cards?

by Zacks Equity Research

Investors will focus on revenue growth and other pipeline updates, when Tilray (TLRY) reports second-quarter 2020 results.

Kinjel Shah headshot

5 Biotech Stocks Set to Outpace Q2 Earnings Estimates

by Kinjel Shah

Let us take a look at some biotech stocks that are poised to beat on second-quarter earnings.

BioNTech (BNTX) to Report Q2 Earnings: What's in Store?

by Zacks Equity Research

During BioNTech's (BNTX) upcoming Q2 earnings conference, investors will keep track of the advancement of its COVID-19 vaccine candidate being developed in partnership with Pfizer.

Intercept Pharmaceuticals (ICPT) Expected to Beat Earnings Estimates: What to Know Ahead of Q2 Release

by Zacks Equity Research

Intercept (ICPT) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Biotech Stock Roundup: GILD Prices Remdesivir, VXRT Rises, ICPT Plunges & More

by Zacks Equity Research

The biotech sector remains in focus with updates on coronavirus treatments and other pipeline developments.

Intercept Slumps as the FDA Issues CRL to NASH Candidate

by Zacks Equity Research

Intercept (ICPT) down on receipt of CRL for its NDA seeking approval of OCA for the treatment of fibrosis due to nonalcoholic steatohepatitis (NASH).

Company News for Jun 30, 2020

by Zacks Equity Research

Companies in the news are: KNSA, TLSA, COTY, ICPT

Why Is Intercept (ICPT) Down 9.4% Since Last Earnings Report?

by Zacks Equity Research

Intercept (ICPT) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.